abrdn plc decreased its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 56.5% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 82,830 shares of the company's stock after selling 107,571 shares during the period. abrdn plc owned 0.07% of Vaxcyte worth $9,465,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in PCVX. Riverview Trust Co purchased a new stake in shares of Vaxcyte in the 3rd quarter valued at about $27,000. Fifth Third Bancorp purchased a new stake in shares of Vaxcyte in the 2nd quarter valued at about $35,000. Fidelis Capital Partners LLC purchased a new stake in shares of Vaxcyte in the 1st quarter valued at about $37,000. Blue Trust Inc. raised its holdings in shares of Vaxcyte by 33.5% in the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company's stock valued at $42,000 after acquiring an additional 93 shares in the last quarter. Finally, J.Safra Asset Management Corp raised its holdings in shares of Vaxcyte by 649.4% in the 2nd quarter. J.Safra Asset Management Corp now owns 607 shares of the company's stock valued at $46,000 after acquiring an additional 526 shares in the last quarter. Hedge funds and other institutional investors own 96.78% of the company's stock.
Several analysts have weighed in on PCVX shares. Leerink Partners raised their price target on Vaxcyte from $106.00 to $153.00 and gave the company an "outperform" rating in a report on Tuesday, September 3rd. Jefferies Financial Group increased their price objective on Vaxcyte from $108.00 to $129.00 and gave the company a "buy" rating in a research report on Tuesday, September 3rd. Bank of America increased their price objective on Vaxcyte from $101.00 to $140.00 and gave the company a "buy" rating in a research report on Wednesday, September 4th. Mizuho increased their price objective on Vaxcyte from $113.00 to $163.00 and gave the company an "outperform" rating in a research report on Tuesday, September 10th. Finally, Needham & Company LLC increased their price objective on Vaxcyte from $95.00 to $140.00 and gave the company a "buy" rating in a research report on Tuesday, September 3rd. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $147.50.
Check Out Our Latest Report on Vaxcyte
PCVX opened at $107.29 on Friday. The stock's 50 day simple moving average is $108.94 and its 200 day simple moving average is $85.87. Vaxcyte, Inc. has a 1 year low of $46.16 and a 1 year high of $121.06. The firm has a market cap of $11.97 billion, a price-to-earnings ratio of -22.93 and a beta of 1.01.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($1.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.04. During the same period in the prior year, the business earned ($0.70) EPS. As a group, sell-side analysts anticipate that Vaxcyte, Inc. will post -4.33 EPS for the current year.
In other Vaxcyte news, CFO Andrew Guggenhime sold 42,000 shares of the stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $115.39, for a total value of $4,846,380.00. Following the completion of the sale, the chief financial officer now owns 90,383 shares in the company, valued at approximately $10,429,294.37. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Vaxcyte news, CFO Andrew Guggenhime sold 42,000 shares of the stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $115.39, for a total value of $4,846,380.00. Following the completion of the sale, the chief financial officer now owns 90,383 shares in the company, valued at approximately $10,429,294.37. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Grant Pickering sold 15,000 shares of the stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $78.98, for a total value of $1,184,700.00. Following the completion of the sale, the chief executive officer now owns 478,888 shares of the company's stock, valued at approximately $37,822,574.24. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 92,098 shares of company stock worth $9,937,773 in the last ninety days. 3.10% of the stock is owned by insiders.
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.